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ABSTRACT Kinetics studies of the cardiac Ca-ATPase expressed in Sf21 cells (Spodoptera frugiperda insect cells) have
been carried out to test the hypotheses that phospholamban inhibits Ca-ATPase cycling by decreasing the rate of the E1Ca
to E1Ca transition and/or the rate of phosphoenzyme hydrolysis. Three sample types were studied: Ca-ATPase expressed
alone, Ca-ATPase coexpressed with wild-type phospholamban (the natural pentameric inhibitor), and Ca-ATPase coex-
pressed with the L37A-phospholamban mutant (a more potent monomeric inhibitor, in which Leu37 is replaced by Ala).
Phospholamban coupling to the Ca-ATPase was controlled using a monoclonal antibody against phospholamban. Gel
electrophoresis and immunoblotting confirmed an equivalent ratio of Ca-ATPase and phospholamban in each sample (1 mol
Ca-ATPase to 1.5 mol phospholamban). Steady-state ATPase activity assays at 37°C, using 5 mM MgATP, showed that the
phospholamban-containing samples had nearly equivalent maximum activity (0.75 molnmol Ca-ATPase1min1 at 15
M Ca2), but that wild-type phospholamban and L37A-phospholamban increased the Ca-ATPase KCa values by 200 nM and
400 nM, respectively. When steady-state Ca-ATPase phosphoenzyme levels were measured at 0°C, using 1 M MgATP, the
KCa values also shifted by 200 nM and 400 nM, respectively, similar to the results obtained by measuring ATP hydrolysis at
37°C. Measurements of the time course of phosphoenzyme formation at 0°C, using 1 M MgATP and 268 nM ionized [Ca2],
indicated that L37A-phospholamban decreased the steady-state phosphoenzyme level to a greater extent (45%) than did
wild-type phospholamban (33%), but neither wild-type nor L37A-phospholamban had any effect on the apparent rate of
phosphoenzyme formation relative to that of Ca-ATPase expressed alone. Measurements of inorganic phosphate (Pi) release
concomitant with the phosphoenzyme formation studies showed that L37A-phospholamban decreased the steady-state rate
of Pi release to a greater extent (45%) than did wild-type phospholamban (33%). However, independent measurements of
Ca-ATPase dephosphorylation after the addition of 5 mM EGTA to the phosphorylated enzyme showed that neither wild-type
phospholamban nor L37A-phospholamban had any effect on the rate of phosphoenzyme decay relative to Ca-ATPase
expressed alone. Computer simulation of the kinetics data indicated that phospholamban and L37A-phospholamban
decreased twofold and fourfold, respectively, the equilibrium binding of the first Ca2 ion to the Ca-ATPase E1 intermediate,
rather than inhibiting rate of the ECa to ECa transition or the rate of phosphoenzyme decay. Therefore, we conclude that
phospholamban inhibits Ca-ATPase cycling by decreasing Ca-ATPase Ca2 binding to the E1 intermediate.
INTRODUCTION
Phospholamban is a 52-amino acid integral membrane pro-
tein of cardiac sarcoplasmic reticulum (SR), which is the
principal regulator of the Ca-ATPase in this membrane
system. The Ca-ATPase is a 110-kDa integral membrane
protein of cardiac SR that transports Ca2 ions into the SR
to promote cardiac muscle relaxation (reviewed by Simmer-
man and Jones, 1998). Phospholamban interacts with the
Ca-ATPase at specific cytoplasmic binding sites (Toyofuku
et al., 1994a,b), but transmembrane interactions between the
two proteins also appear to be intimately involved in the
inhibition process (Kimura et al., 1996). It has been well
demonstrated that dephosphorylated phospholamban inhib-
its Ca-ATPase activity by decreasing enzyme sensitivity to
Ca2 for activation of ATP hydrolysis (MacLennan et al.,
1992; Voss et al., 1994; Autry and Jones, 1997). The inhi-
bition of the Ca-ATPase is relieved by phosphorylation of
phospholamban at Ser16 or Thr17 or by the binding of a
monoclonal antibody against the cytoplasmic domain of
phospholamban (Autry and Jones, 1997), resulting in a
marked increase in Ca-ATPase activity. The majority of
studies have shown that phospholamban does not alter Ca-
ATPase Vmax significantly; it alters only the [Ca
2] required
to produce maximum activity (Kranias, 1985; MacLennan
et al., 1992; Jones and Field, 1993; Cantilina et al., 1993;
Reddy et al., 1996; Autry and Jones, 1997; Chu et al., 1998),
although this point is still contested (Antipenko et al.,
1997a; Simmerman and Jones, 1998).
Despite our knowledge of the functional effects of phos-
pholamban on Ca-ATPase activity, fundamental questions
remain about the mechanism by which phospholamban ex-
erts its inhibitory interaction (Scheme 1). A number of
investigators have previously studied the effect of phospho-
lamban on the partial reactions of the Ca-ATPase cycle
(Shigekawa et al., 1976; Jones et al., 1978; Sumida et al.,
1978, 1980; Tada et al., 1979, 1980; Kranias et al., 1980;
Cantilina et al., 1993; Hughes et al., 1994; Antipenko et al.,
1997a, 1999). Unfortunately, these studies have provided
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conflicting results about which Ca-ATPase partial reac-
tion(s) are affected by phospholamban, and thus a unified
model has been slow to emerge. Several studies (Tada et al.,
1979; Antipenko et al., 1997a, 1999) have suggested that
phospholamban controls Ca-ATPase activity by decreasing
by twofold the rate of phosphoenzyme decomposition. Ki-
netics studies of Ca-ATPase in skeletal muscle SR by
Froehlich and Taylor (1975, 1976) have shown that Ca-
ATPase phosphoenzyme decomposition is a two-step pro-
cess (steps 5 and 6, Scheme 1), in which E2P is first
hydrolyzed to E2Pi, followed by the release of inorganic
phosphate (Pi) from the enzyme forming the E2 intermedi-
ate. The relative rates of these two steps are modulated by
a variety of factors, including ionized [Ca2], suggesting
that the inhibition of Ca-ATPase phosphoenzyme decom-
position by phospholamban can account for the effect of
phospholamban on the [Ca2] dependence of Ca-ATPase
activity (Simmerman and Jones, 1998). In contrast, how-
ever, a number of investigators (Cantilina et al., 1993;
Negash et al., 1996; Antipenko et al., 1997a) have provided
evidence that phospholamban inhibits Ca-ATPase cycling
by increasing the activation energy of a slow Ca2-depen-
dent conformational change, which is required for ATP-
dependent phosphoenzyme formation, and which occurs
during the E1 2Ca2 to E1Ca2 transition (step 2, Scheme
1). Previously, Inesi et al. (1980) showed that the coopera-
tive binding of two Ca2 ions to the Ca-ATPase occurs in
two discrete steps separated by a conformational change
(Scheme 2). The binding of the first Ca2 ion to the Ca-
ATPase E1 intermediate (forming E1Ca) stimulates a con-
formational change in the enzyme (E1Ca to E1Ca), which
increases the affinity of the enzyme for binding the second
Ca2 ion, forming E1Ca2. Subsequently, Cantilina et al.
(1993) proposed that phospholamban decreases by 10-fold
the forward and reverse rate constants for the E1Ca to
E1Ca transition. While this model can account for the shift
in the [Ca2] dependence of Ca-ATPase activity induced by
phospholamban, the proposal remains to be tested quantita-
tively. Clearly, these mechanistic issues have to be resolved
to provide a better understanding of the inhibition of Ca-
ATPase by phospholamban.
In the present work, we have carried out kinetics studies
of the cardiac Ca-ATPase to test the hypotheses that phos-
pholamban inhibits Ca-ATPase cycling by decreasing the
rate of the E1Ca to E1Ca transition and/or the rate of
phosphoenzyme hydrolysis. To assist in these studies, we
have made use of the baculovirus-Sf21 insect cell (Spodop-
tera frugiperda insect cell) expression system to study Ca-
ATPase-phospholamban functional interactions. An advan-
tage of this system is that sufficient expressed material is
produced to allow detailed kinetics characterizations, in-
cluding phosphoenzyme formation and decomposition stud-
ies. Expression systems previously used to study the regu-
latory effects of phospholamban on the Ca-ATPase have
yielded much lower levels of protein (discussed in Autry
and Jones, 1997), precluding the type of kinetics studies
presently reported. In addition, this expression system fa-
cilitates the study of the phosphorylation and dephosphor-
ylation kinetics of the cardiac Ca-ATPase expressed by
itself, independently of the influence of phospholamban,
compared directly with parallel kinetics studies of the Ca-
ATPase coexpressed with wild-type pentameric phospho-
lamban (the natural inhibitor) or with the monomeric L37A-
phospholamban mutant (a potent superactive mutant or
“super shifter”) (Simmerman et al., 1996; Autry and Jones,
1997; Kimura et al., 1997). Any effect of wild-type phos-
pholamban on Ca-ATPase kinetics would be expected to be
amplified in the presence of the more potent L37A-phos-
pholamban and absent when the Ca-ATPase is expressed
alone without phospholamban. Finally, to further document
the specific effect of phospholamban on Ca-ATPase kinet-
ics, we took advantage of our monoclonal antibody 2D12
raised against phospholamban (Sham et al., 1991; Briggs et
al., 1992), which selectively reverses phospholamban inhib-
itory effects on Ca-ATPase, like phospholamban phosphor-
ylation (Cantilina et al., 1993; Antipenko et al., 1997b). Use
of the anti-phospholamban antibody allowed large amounts
of membrane material to be utilized for kinetics studies,
removing the need for protein kinase activation and inhibi-
tion of phosphatase activity during lengthy kinetics exper-
iments. Our results show that phospholamban acts by de-
creasing Ca-ATPase affinity for Ca2, not by slowing the
rate of the E1Ca to E1Ca conformational transition (Can-
tilina et al., 1993; Negash et al., 1996; Antipenko et al.,
1997a) or the rate of dephosphorylation of the E2P inter-
mediate (Tada et al., 1979; Antipenko et al., 1997a, 1999),
as previously proposed by others.
Scheme 1.
Scheme 2.
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MATERIALS AND METHODS
Materials
[-32P]ATP was purchased from ICN, and 125I-labeled protein A was
purchased from DuPont NEN. Prestained molecular weight standards and
polyvinylidene difluoride (PVDF) membranes were purchased from Bio-
Rad. Sf21 insect cells were purchased from Invitrogen, and the BaculoGold
system was obtained from Pharmigen.
Protein expression and isolation
Recombinant baculoviruses containing cDNA inserts for canine cardiac
Ca-ATPase (SERCA2a) or canine phospholamban were prepared using the
BaculoGold system as recently described (Autry and Jones, 1997). Wild-
type canine SERCA2a and canine phospholamban (wild type and mutant)
were expressed in Sf21 cells grown in suspension (1.5  106 cells/ml) at
27°C in Grace’s insect cell medium (Life Technologies) supplemented
with 10% fetal bovine serum (Atlanta Biologicals) and containing 0.1%
Pluronic F-68 (Life Technologies). Microsomes were isolated from insect
cells harvested 48 h after infection with baculoviruses. For expression of
the Ca-ATPase alone, a multiplicity of infection of 10 (viruses per cell) was
used. For coexpression of the Ca-ATPase and phospholamban, a multi-
plicity of infection of 15 was used for SERCA2a and 5 for phospholamban
(wild type and mutant). Virus-infected Sf21 cells in 600 ml of suspension
(9  108 cells) were sedimented and then washed twice with an ice-cold
solution containing 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4
mM KH2PO4 (pH 7.4), by centrifugation for 5 min at 1500 rpm at 4°C in
an IEC GP8R refrigerated centrifuge. The washed cells were resuspended
in 100 ml of ice-cold 10 mM NaHCO3 containing 10 g/ml aprotinin, 2
g/ml leupeptin, 1 g/ml pepstatin A, and 0.1 mM pefabloc, and then
homogenized for 90 s with a Brinkman Polytron (50% full speed) in a
cold room. The homogenate was centrifuged for 20 min at 9000 rpm
(10,000  g), 4°C, in a Sorvall SS34 rotor. The supernatant was collected
and the Sf21 insect cell microsomes were pelleted by centrifugation for 35
min at 26,000 rpm (70,000 g), 4°C, in a Beckman Ti45 rotor. The pellets
were resuspended to 5 mg/ml in 250 mM sucrose, 30 mM histidine (pH
7.4) and stored in small aliquots at 50°C. Protein concentrations were
determined by the method of Lowry et al. (1951), using bovine serum
albumin (Sigma) as a standard. The average yield per 600 ml of infection
was 30 mg of microsomal protein. Additional details of the purification and
characterization of Sf21 insect cell microsomes are provided elsewhere
(Autry and Jones, 1997).
Electrophoresis and immunoblotting
Before electrophoresis, samples were solubilized at 37°C for 5 min in a
dissociation medium that contained 62.5 mM Tris (pH 6.8), 5% glycerol,
5% sodium dodecyl sulfate (SDS), 40 mM dithiothreitol, and 0.0025%
bromphenol blue. Sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) (BioRad Mini-Protean II System) was conducted by
the method of Porzio and Pearson (1977), using 8% polyacrylamide.
Kaleidoscope prestained molecular weight markers (BioRad) were used as
standards. Gels were stained using GelCode Blue Stain reagent (Pierce), or
proteins were transferred (BioRad Mini-Transblot System) to PVDF mem-
branes (BioRad) for immunoblotting. The transfer protocol was carried out
according to the instructions provided by the manufacturer, except that
methanol was excluded from the transfer buffer. We found that the use of
methanol in the transfer buffer resulted in a significant amount of protein
being retained in the polyacrylamide gel after transfer. In addition, a
second membrane sheet was used for each blot, to capture protein that
migrated through the first sheet without binding. The PVDF membranes
were probed with anti-SERCA2a monoclonal antibody 2A7-A1 for detec-
tion of SERCA2a or with anti-phospholamban monoclonal antibody 2D12
for detection of phospholamban (Movsesian et al., 1994). Antibody-bind-
ing proteins were visualized using [125I]-protein A, and labeling intensities
from both membranes were quantified and summed using a Molecular
Dynamics Phosphorimager SI. For quantitative immunoblotting,
SERCA2a was purified from canine cardiac SR vesicles, and recombinant
canine phospholamban was purified from Sf21 insect cells by 2A7-A1 or
2D12 monoclonal antibody affinity chromatography, respectively. These
samples were used as standards to quantify the amount of SERCA2a and
phospholamban in the Sf21 insect cell microsomes (described below). We
found that for SERCA2a, 80% of the blot intensity appeared on the first
membrane, and the remaining 20% on the second membrane. For pentam-
eric phospholamban, more than 99% of the blot intensity appeared on the
first membrane, with only a faint trace of blot intensity on the second
membrane. For monomeric phospholamban, 85% of the blot intensity
appeared on the first membrane, with the remaining 15% of the intensity
localized to the second membrane. No GelCode Blue-stained protein bands
in the vicinity of SERCA2a or phospholamban were retained on the
polyacrylamide gel after transfer to the PVDF membranes.
SERCA2a ATPase assay
[Ca2]-dependent ATPase activity of SERCA2a in the Sf21 insect cell
microsomes was measured colorimetrically at 37°C, using a malachite
green-ammonium molybdate assay (Lanzetta et al., 1979; Mahaney et al.,
1995). SERCA2a incubation tubes contained 0.05 mg/ml protein in 50 mM
3-[N-morpholino]propanesulfonic acid (MOPS) (pH 7.0), 3 mM MgCl2,
100 mM KCl, 1 mM EGTA, and 0–1.0 mM CaCl2, to give the desired
ionized [Ca2], as previously determined (Autry and Jones, 1997). To
initiate the ATPase reaction, 5 mM MgATP was added to the incubation
tube. After 10 min of reaction at 37°C, a 50-l aliquot of the incubation
mixture was transferred into an assay tube containing 1.6 ml of malachite
green-ammonium molybdate reagent at room temperature. After 30 s, the
colorimetric reaction was quenched by the addition of 200 l of 34%
sodium citrate (Sigma) into the assay tube. For the determination of
phosphate, a standard curve was constructed using aliquots of a 0.65 mM
phosphate standard solution (Sigma), assayed in a similar fashion. After 30
min of color development, the absorbance of the malachite green reagent
was measured at 660 nm. SERCA2a samples were pretreated with the Ca2
ionophore A23187 (CalBiochem) (20 g/mg of total protein) before ad-
dition to the incubation tubes. Before preparation of the incubation tubes,
the SERCA2a samples were incubated for 20 min on ice without or with
affinity-purified anti-phospholamban monoclonal antibody 2D12, at an
antibody-to-total protein weight ratio of 1:1 (Autry and Jones, 1997).
ATP-dependent phosphoenzyme formation
Ca-ATPase phosphoenzyme formation experiments were carried out using
ice-cold solutions. Mixing was conducted in a cold room (2  1°C) to
prevent significant sample warming during additions and vortexing. Before
phosphoenzyme formation, the SERCA2a-containing Sf21 insect cell mi-
crosomes were permeabilized by the addition of Ca2 ionophore A23187
(20 g/mg total protein). Next, 0.25 ml of a solution containing 0.2 mg
Sf21 microsomes/ml in 50 mM MOPS (pH 7.0), 3 mM MgCl2, 100 mM
KCl, 1 mM EGTA was placed in a 7-ml glass scintillation vial (VWR) and
set on ice. The EGTA preincubation was designed to remove all traces of
Ca2 from the medium and to stabilize SERCA2a in a Ca2-free state. To
initiate phosphoenzyme formation, 0.25 ml of an ice-cold solution con-
taining 50 mM MOPS (pH 7.25), 3 mM MgCl2, 100 mM KCl, 1 mM
EGTA, varying CaCl2, and 2 M [-
32P]ATP (20,000 cpm/nmol) was
added rapidly (less than 1 s) to the microsome-containing vial with inter-
mittent vortexing. The final conditions after mixing were 50 mM MOPS
(pH 7.0), 3 mM MgCl2, 100 mM KCl, 1 mM EGTA, and either 0.5 mM
CaCl2 (ionized [Ca
2]final  268 nM), 0.7 mM CaCl2 (ionized [Ca
2]final
 625 nM), or 1 mM CaCl2 (ionized [Ca
2]final  15 M). The reaction
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was allowed to proceed for different times before quenching by the rapid
addition of 0.5 ml of ice-cold 9% perchloric acid 6 mM H3PO4, followed
by vigorous vortexing. Blank tubes were prepared by first adding 0.5 ml of
quench solution to the 0.25-ml microsome-containing solution, vortexing
vigorously, then adding 0.25 ml of the ATP-containing solution. A 25-l
aliquot of 10 mg/ml bovine serum albumin was added to each quenched
sample to act as a carrier protein during the processing of the sample vials.
The quenched samples were pelleted by centrifugation for 10 min at
3000  g, 4°C, in an IEC GP8R refrigerated centrifuge, and then washed
three times by similar centrifugation using an ice-cold solution of 5%
trichloroacetic acid, 6% polyphosphoric acid, 4 mM H3PO4, and 5 mM
nonradioactive ATP. Pellet recovery after washing was greater than 95%,
determined by protein assay. The final pellets were dissolved in 5 ml 1 N
NaOH, and the [32P]phosphoenzyme was assayed by counting the Ceren-
kov radiation.
Separation and analysis of 32Pi in the
presence of [-32P]ATP
[32P]Pi liberation during phosphoenzyme formation was assayed according
to Mahaney et al. (1995). After the first sedimentation of the quenched
phosphorylation sample, 0.5 ml of the supernatant was added to 0.5 ml of
a 2% aqueous charcoal slurry. The sample was vortexed and centrifuged
for 10 min at 3000 g, 4°C. A 0.5-ml aliquot of the supernatant was added
to another 0.5 ml of a 2% aqueous charcoal slurry, vortexed, and centri-
fuged as before. A 0.5-ml aliquot of the supernatant from this second
centrifugation was added to 0.75 ml of water saturated with 1:1 isobutanol:
xylene contained in a 16  100 mm borosilicate assay tube and vortexed.
To each tube was added 0.4 ml of 5% ammonium molybdate (in 4 N HCl)
reagent, and the samples were vortexed briefly. Complex formation be-
tween Pi and the molybdate (yellow color development) was allowed to
proceed for 15 min. After the incubation, 2 ml of water-saturated 1:1
isobutane:xylene was added to each tube and vortexed 3  10 s with 10 s
between vortexing periods. The phases were allowed to separate for 10
min, after which 1 ml of the organic (upper) phase was pipetted into 5 ml
of 1 N NaOH contained in a 7-ml glass scintillation vial. The vials were
capped and shaken until the yellow color disappeared, and 32P was assayed
by counting the Cerenkov radiation. All steps involving organic solvents
were carried out in a fume hood, and tubes containing solvents were
covered when not in use, to minimize solvent loss due to evaporation.
Dephosphorylation of the
phosphoenzyme by EGTA
SERCA2a samples were phosphorylated with 1 M [-32P]ATP at 0°C for
30 s as described above, followed by the rapid addition of 0.25 ml of
solution containing 50 mM MOPS (pH 7.0), 3 mM MgCl2, 100 mM KCl,
variable CaCl2 (as defined above), and 15 mM EGTA. The final [EGTA]
after mixing was 5 mM, which was sufficient to reduce the ionized [Ca2]
to less than 1 nM. The reaction was allowed to proceed for various time
periods before quenching by the rapid addition of 0.75 ml of ice-cold 9%
perchloric acid  6 mM H3PO4, followed by vigorous vortexing. A
zero-time sample was obtained by quenching the phosphorylation reaction
at 30 s and adding 0.5 ml of the EGTA chase solution to the quenched
sample. Sample blanks were prepared as described above, except for the
addition of 0.5 ml of the EGTA-containing solution to the quenched
sample. The quenched samples were processed and assayed for 32P-
containing enzyme as described above.
Curve fitting and kinetic modeling
[Ca2]-dependent ATPase activity data and phosphoenzyme kinetics data
were fit using the program KFIT written by N. C. Millar. The amplitude
and rate parameters were constrained to positive numbers and allowed to
vary without bound during the fits. The best fits of the data were chosen on
the basis of optimization of the determination coefficient, R2, and/or
minimization of the sum-of-squares error, 2. Simulation of the time
courses of phosphoenzyme formation, Pi liberation, and EP decay were
carried out using the program KINSIM (Barshop et al., 1983), the reactions
of Scheme 3, and the rate constants presented in Table 6 (Results). Because
the rate of the E1P-to-E2P transition (Scheme 1, step 4) is significantly
faster (	300 s1; Mahaney et al., 1995) than any of the other steps under
the conditions of our experiments (described below), the phosphorylated
Ca-ATPase was treated as a single species in the simulations. Initial values
for the rate constants were obtained in the present study (see Results) and
from Cantilina et al. (1993). The rate constants reported by Cantilina et al.
define the Ca-ATPase cycle at 25°C; thus these constants were reduced by
a factor of 5 for the present simulations (0°C), based on the general
assumption that the reaction rates decreased by a factor of 2 for each 10°C
decrease in temperature (i.e., Q10 of 2). The EGTA  Ca
2 equilibration,
which occurred upon the simultaneous addition of Ca2 and ATP to the
microsomes preequilibrated in EGTA, was not modeled in the simulations,
because this equilibration is rapid (Smith et al., 1984; Harrison and Bers,
1989) relative to the reaction steps of the SERCA2a cycle under our
experimental conditions. The amplitude and rate parameters were con-
strained to positive numbers and allowed to vary without bound during the
simulations. The goodness of fit of the simulation to the data was judged
by maximizing the R2 value for the simulation.
RESULTS
Protein expression, characterization, and assay
For this study, SERCA2a was expressed in Sf21 insect cells
alone, coexpressed with wild-type phospholamban, or co-
expressed with monomeric mutant L37A-phospholamban
(Autry and Jones, 1997), and isolated as Sf21 insect cell
microsomes. SDS-PAGE (Fig. 1 A) and immunoblotting
(Fig. 1 B) of the Sf21 microsomes indicated that Sf21 cells
produced similar amounts of recombinant Ca-ATPase and
phospholamban in the expressed samples. Furthermore, the
gel and the blots of the microsomal samples (Fig. 1, A and
B, lanes 1–3) confirmed that there was almost no high-
molecular-weight SERCA2a aggregate in the expressed
samples. The amount of SERCA2a and phospholamban in
the Sf21 microsome samples was determined by quantita-
tive immunoblotting (Fig. 1, B–D), using purified
SERCA2a and phospholamban samples as standards. As
shown in Fig. 1, the purified proteins (empty symbols)
provided linear standard curves that showed SERCA2a mi-
crosomes contained 8.3% SERCA2a and no phospholam-
ban, SERCA2a  wild-type phospholamban microsomes
contained 3% SERCA2a and 0.26% phospholamban, and
SERCA2a  L37A-phospholamban microsomes contained
4.6% SERCA2a and 0.36% phospholamban (Table 1). The
blot data for the expressed samples shown in Fig. 1 (C and
D) was obtained using 10 g of microsomal protein. Similar
experiments conducted using 5 g of microsomal protein
(not shown) provided nearly identical results. Thus, even
though the SERCA2a blot intensity of the SERCA2a alone
sample is greater than that of the standards used (Fig. 1 C,
diamonds), the extrapolated slope of the standard curve
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provides a reliable value for the amount of SERCA2a in this
expressed sample. Using the molecular masses for canine
SERCA2a (110,000 Da) (Autry and Jones, 1997) and phos-
pholamban (6080 Da) (Fujii et al., 1987), we determined
that the molar ratio of SERCA2a:phospholamban was 1:1.6
for the SERCA2a  wild-type phospholamban sample and
1:1.5 for the L37A-phospholamban sample. The similarity
of the SERCA2a-to-phospholamban ratio in the two phos-
pholamban-containing samples facilitated direct and quan-
titative comparison of the effects of wild-type versus L37A-
phospholamban on SERCA2a phosphorylation kinetics.
To test the activity of the expressed SERCA2a and the
functional coupling between SERCA2a and phospholamban
in Sf21 cell microsomes, ATPase assays were conducted at
37°C at a series of [Ca2] in the presence and absence of
anti-phospholamban monoclonal antibody 2D12, which re-
verses the inhibitory interaction between phospholamban
and SERCA2a (Briggs et al., 1992; Sham et al., 1991). The
ATPase activity of the expressed SERCA2a displayed the
usual sigmoidal [Ca2] dependence, and the maximum
steady-state activities per mg of microsomal protein for the
three sample types were SERCA2a alone, 0.6
molmg1min1; SERCA2a  wild-type phospholam-
ban, 0.2 molmg1min1; and SERCA2a  L37A-phos-
pholamban, 0.3 molmg1min1. Differences in the max-
imum activities correlated with differences in Ca-ATPase
expression levels between the different samples deduced
from the SDS-PAGE and immunoblot analysis. That is,
when corrected for the amount of SERCA2a in each sample
type, the maximum activity for each sample was 0.75
FIGURE 1 SDS-PAGE and immunoblotting of canine SERCA2a and phospholamban expressed in Sf21 microsomes. (A) GelCode Blue-stained SDS gel
(10 g protein per lane) showing Sf21 microsomes containing SERCA2a alone (lane 1), SERCA2a  wild-type phospholamban (lane 2), and SERCA2a
 L37A-phospholamban (lane 3). (B) Corresponding immunoblot of the SDS gel shown in A, developed with SERCA2a antibody 2A7-A1 (top) or
phospholamban antibody 2D12 (bottom). PLBp denotes pentameric phospholamban and PLBm denotes monomeric phospholamban. Lanes A–E contain
0.2–1.0 g purified SERCA2a (top) or 0.02–0.1 g purified phospholamban (bottom). Lanes 1–3 contain 10 g of Sf21 microsomal protein per lane and
correspond to SERCA2a alone, SERCA2a  wild type phospholamban, and SERCA2a  L37A-phospholamban, respectively. (C and D) Standard curves
(empty symbols) constructed using purified SERCA2a and phospholamban, respectively, showing the relationship between blot intensity and amount of
protein loaded. The filled symbols correspond to the blot intensities obtained using Sf21 microsomes containing SERCA2a alone (), SERCA2a  wild
type phospholamban (Œ), and SERCA2a  L37A-phospholamban (f), which were used in conjunction with the standard curves to deduce the amount of
SERCA2a or phospholamban in each of the sample types studied (Table 1). An identical experiment conducted using 5 g of Sf21 microsomal protein per
lane (not shown) produced equivalent results.
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mol Pi produced per minute per nmol SERCA2a (Table 1).
For comparison, a similar analysis was carried out using dog
cardiac SR (CSR) vesicles. The ATPase activity of the CSR
vesicles per mg of microsomal protein measured under
identical conditions was 2.1 molmg1min1. When cor-
rected for the amount of SERCA2a in this preparation of
CSR, which was reported as 30% (Jones et al., 1979; Autry
and Jones, 1997), the maximum activity of the sample was
0.77 molnmol SERCA2a1min1, which is identical to
that of the expressed samples (Table 1). Thus there were no
differences in SERCA2a specific activity between the ex-
pressed samples, which were identical to that in dog cardiac
SR.
SERCA2a expressed without phospholamban had a high
apparent Ca2 affinity (ionized [Ca2] giving half-maxi-
mum activation of the Ca-ATPase, KCa  200 nM), which
was unaffected by treatment of the sample with phospho-
lamban monoclonal antibody (Table 1). When coexpressed
with wild-type phospholamban, the SERCA2a activity
curve was shifted to the right relative to that of SERCA2a
expressed alone, resulting in an increase in KCa to 420 nM.
When coexpressed with the monomeric mutant L37A-phos-
pholamban, a potent super shifter (Autry and Jones, 1997;
Kimura et al., 1997), the SERCA2a activity curve was
shifted to the right to a greater extent, resulting in an
increase in KCa to 800 nM. For both phospholamban-con-
taining samples, treatment with anti-phospholamban anti-
body 2D12 shifted the Ca2 activation curve to the left,
resulting in twofold decreased KCa values. The KCa value for
the antibody-treated SERCA2a  wild-type phospholam-
ban sample was equivalent to that obtained for SERCA2a in
the absence of phospholamban, whereas the KCa value for
the antibody-treated SERCA2a  L37A-phospholamban
sample was greater than that of the SERCA2a alone sample
(Table 1). This characteristic of the SERCA2a  L37A-
phospholamban sample has been reported previously (Autry
and Jones, 1997), and it is a common feature of the super-
shifting monomeric phospholamban mutants containing
mutations in the leucine-isoleucine zipper domain (Autry
and Jones, 1998). Note that the absolute amount of the KCa
shift by the antibody for the L37A-phospholamban mutant
(0.4 M shift) was two times greater than the shift for
wild-type phospholamban (0.2 M shift). This demon-
strates that the antibody effect on the L37A-phospholamban
mutant is amplified compared to the antibody effect on
wild-type phospholamban, even though the shift in Ca af-
finity by L37A-phospholamban on the Ca-ATPase is not
reversed completely by the antibody. This suggests that the
antibody is acting in a mechanistically realistic way on
L37A-phospholamban/Ca-ATPase interactions, even
though it is not capable of totally reversing the inhibitory
effect of this potent mutant on Ca-ATPase activity. High
ionized [Ca2], however, is capable of reversing the inhib-
itory effect completely (see below). For comparison, the
KCa values measured for dog cardiac SR were 400 nM and
170 nM for the sample without and with pretreatment with
anti-phospholamban antibody, respectively, similar to the
expressed SERCA2a  wild-type phospholamban sample.
Ca-ATPase activities were identical between all three sets
of microsomal membranes when measured at saturating
ionized [Ca2], and under this Vmax condition the monoclo-
nal antibody produced no effect (Table 1). Lack of effect of
the monoclonal antibody on the Ca-ATPase Vmax in native
cardiac SR vesicles is well known (Simmerman and Jones,
1998). The results show that phospholamban was function-
ally coupled to Ca-ATPase in the two phospholamban-
coexpressed samples, similar to that observed in native
cardiac SR vesicles. Furthermore, the results confirm earlier
TABLE 1 Characterization of SERCA2a and phospholamban coexpressed in Sf21 insect cells
Sample Type
Expression SERCA2a ATPase Activity at 37°C and 5 mM MgATP
SERCA2a PLB
SERCA2a:PLB Vmax Vmax Kca Kca
ratio Ab Ab Ab Ab
(% total protein) (% total protein) (mol:mol) (mol  nmol SERCA2a1  min1) (M)
SERCA2a alone 8.3 0.00 1:0 0.80  0.05 0.80  0.05 0.20  0.02 0.19  0.02
SERCA2a  WT-PLB 3.0 0.26 1:1.6 0.74  0.10 0.74  0.10 0.42  0.03 0.22  0.02
SERCA2a  L37A-PLB 4.6 0.36 1:1.5 0.72  0.10 0.72  0.10 0.80  0.03 0.40  0.03
Wild-type Ca-ATPase and phospholamban (wild-type or L37A-PLB) were coexpressed using the baculovirus-Sf21 insect cell expression system and
isolated as insect cell microsomes. Sf21 insect cell microsomes were subjected to SDS-PAGE, and the protein bands were transferred from the gel onto
PVDF membranes for immunoblotting. The amount of SERCA2a or phospholamban in the Sf21 microsomes was obtained from standard curves constructed
using various amounts of purified SERCA2a (0–1 g) or phospholamban (0–0.1 g) included on the same gel as the expressed samples (Fig. 1). The molar
ratio of SERCA2a to phospholamban in each sample was determined using the weight of each protein divided by the respective molecular weight (110,000
g/mol for SERCA2a (Autry and Jones, 1997) and 6080 g/mol for phospholamban (Fujii et al., 1987)). The SERCA2a ATPase activity of each sample was
assayed at 37°C, using 5 mM MgATP and various [Ca2]free levels between 30 nM and 15 M. Samples were preincubated in the absence (Ab) or
presence (Ab) of anti-phospholamban monoclonal antibody, 2D12, for 20 min on ice before the start of the activity assays. The maximum activity (Vmax)
and [Ca2] required for half-maximum activity (KCa) were determined from Hill fits of the [Ca
2]-dependent ATPase activity for each sample. SERCA2a
ATPase activity is expressed in terms of nmol SERCA2a, according to the amount of SERCA2a per mg of Sf21 cell microsomes for each sample. Errors
denote the spread of triplicate determinations for a single experiment using a single preparation of expressed protein. Experimental repeats using different
preparations gave very similar results.
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observations that the monomeric L37A-phospholamban
mutant is a more potent inhibitor of steady-state Ca-ATPase
activity than wild-type phospholamban, but even the more
potent L37A-phospholamban does not affect the maximum
ATPase activity (Autry and Jones, 1997; Kimura et al.,
1997).
SERCA2a phosphoenzyme formation
The first goal of our kinetics studies was to test the hypoth-
esis that phospholamban inhibits Ca-ATPase cycling by
decreasing by 10-fold the rate of the E1Ca-to-E1Ca tran-
sition (Cantilina et al., 1993). To test this hypothesis, we
measured the effect of phospholamban on ATP-dependent
SERCA2a phosphoenzyme (EP) formation, starting with
the Ca-ATPase in a Ca2-free state. SERCA2a-containing
microsomes were preincubated at 0°C in 1 mM EGTA in
the experimental buffer to remove all traces of Ca2 from
the medium and to stabilize the Ca-ATPase in a Ca2-free
state (Scheme 1). At time 0, an equal volume of the same
ice-cold experimental buffer containing [-32P]ATP (1 M
final) and Ca2 (various levels) was added to the enzyme
solution, and the reaction was allowed to proceed at 0°C for
serial times before acid quenching and determination of
phosphoenzyme formed. Samples were preincubated either
without or with anti-phospholamban monoclonal antibody
2D12 before the initiation of phosphoenzyme formation.
The low temperature and low [ATP] were used to slow the
rate of EP formation and thus allow its measurement by
hand mixing techniques over a 20–30-s time interval after
the addition of ATP. The EGTA preincubation was included
to allow us to measure the effect of phospholamban on the
E1Ca-to-E1Ca transition, which limits the rate of EP
formation under these conditions (Cantilina et al., 1993;
Tada et al., 1980). Specific control experiments of the
expressed enzyme (not shown) showed that the EGTA
preincubation had no deleterious effect on Ca-ATPase sta-
bility, even after a 1-h incubation on ice.
In the first set of experiments, we measured the effect of
phospholamban on the [Ca2] dependence of steady-state
EP levels formed by 1 M ATP at 0°C for SERCA2a
expressed in Sf21 cell microsomes (Fig. 2 and Table 2). The
steady-state EP level of each sample type displayed a sig-
moidal dependence on [Ca2], and the KCa values (Table 2)
of the curves were nearly identical to those obtained from
the [Ca2]-dependent ATPase activity of three SERCA2a
samples measured at 37°C at saturating [ATP] (Table 1).
The maximum steady-state EP level was similar for the
three sample types, in terms of nmol EP formed per mg total
Sf21 microsomal protein: 0.055 nmol EP/mg for SERCA2a
alone, 0.02 nmol EP/mg for SERCA2a  wild type phos-
pholamban, and 0.03 nmol EP/mg for SERCA2a  L37A-
phospholamban. When the raw EP levels were corrected for
Ca-ATPase expression levels in the different samples (Ta-
ble 1), the three samples showed virtually identical maxi-
FIGURE 2 [Ca2] dependence of steady-state phosphoenzyme levels of
SERCA2a in Sf21 microsomes formed by 1 M ATP at 0°C. Steady-state
SERCA2a phosphoenzyme (EP) levels were measured by phosphorylating
Sf21 microsomes (0.1 mg/ml) preincubated in 1 mM EGTA with 1 M
[-32P]ATP and various [Ca2] levels for 30 s at 0°C, followed by acid
quenching and processing as described in Materials and Methods. (A)
SERCA2a expressed alone; (B) SERCA2a coexpressed with wild-type
phospholamban; (C) SERCA2a coexpressed with L37A-phospholamban.
The steady-state EP levels of SERCA2a in Sf21 microsomes pretreated
with phospholamban monoclonal antibody, 2D12, are denoted by empty
circles (E), and the control, untreated microsomes are denoted by the
empty squares (). The data were simulated using the reactions of Scheme
3 and the rate constants in Table 6. Simulation of the antibody-treated data
is denoted by the filled circles (F), and simulation of the control, untreated
data is denoted by the filled squares (f). The curves represent fits of the
data to the Hill equation, which provided the KCa and maximum EP values
(Table 2). Empty symbols represent the average of triplicate measurements
for a single preparation of each sample type. Error bars denote the high and
low values in each average. Additional experiments using different prep-
arations provided equivalent results.
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mum EP levels of0.075 nmol/nmol SERCA2a (Fig. 2 and
Table 2). For comparison, similar experiments using dog
cardiac SR (data not shown) revealed a maximum EP level
of 0.21 nmol/mg SR, which was equivalent to 0.073 nmol/
nmol SERCA2a. This result shows that the phosphorylation
capacity of SERCA2a in the expressed samples was iden-
tical to that of native SERCA2a in cardiac SR. Thus the
relatively low maximum EP levels reported here arose from
the low, subsaturating [ATP] concentration utilized in the
experiment (cf. Froehlich and Taylor, 1975; Tada et al.,
1980) and not from inactive SERCA2a in the expressed
samples.
Ca-ATPase expressed without phospholamban displayed
a Kca of 200 nM for steady-state EP formation, which was
unaffected by treatment of these microsomes with 2D12
(Table 2). When SERCA2a was coexpressed with wild-type
phospholamban, the Kca value increased to 460 nM
(
KCa  210 nM relative to the antibody-treated sample).
When coexpressed with the monomeric mutant L37A-phos-
pholamban, the Kca value increased to a greater extent to
800 nM (
KCa  400 nM relative to the antibody-treated
sample). For both phospholamban-coexpressed samples,
treatment with 2D12 shifted the Ca2 activation curve to the
left, resulting in twofold decreased KCa values. As observed
with measurement of steady-state ATPase activity at 37°C,
the KCa value for the antibody-treated SERCA2a  wild-
type phospholamban sample was not significantly different
from that obtained for expression of SERCA2a in the ab-
sence of phospholamban. In contrast, the KCa value for the
antibody-treated SERCA2a  L37A-phospholamban sam-
ple was greater than that of the SERCA2a alone sample, as
was also observed for the 37°C steady-state activity mea-
surements (Table 1). Similar to the effects of phospholam-
ban on SERCA2a ATPase activity, treatment of each sam-
ple with anti-phospholamban antibody had no effect on the
maximum steady-state EP levels formed, which were iden-
tical between all three sets of microsomes. Thus the results
obtained for formation of steady-state EP levels at 0°C,
using 1 M ATP, mirrored the results obtained for mea-
surement of steady-state ATP hydrolysis at 37°C using 5
mM ATP. Furthermore, the results show that the mono-
meric L37A-phospholamban mutant is a more potent inhib-
itor of SERCA2a steady-state phosphoenzyme formation
than is wild-type phospholamban, but, in analogy to mea-
surements of ATP hydrolysis (Autry et al., 1997; Kimura et
al., 1997), even the more potent L37A-phospholamban does
not affect the maximum SERCA2a steady-state EP level
observed at saturating [Ca2].
In the next set of experiments, we measured the effect of
phospholamban on the time course of EP formation by
SERCA2a in Sf21 cell microsomes at 0°C (Fig. 3 and Table
3). These measurements were carried out for 268 nM
[Ca2]free, which is near the KCa value for each sample, and
at a saturating Ca2 level (15 M [Ca2]free), where phos-
pholamban has no effect on Ca-ATPase activity (Fig. 2 and
Table 1). At 268 nM [Ca2]free (Fig. 3, left), the EP forma-
tion time course for SERCA2a expressed alone (top left)
exhibited a brief lag (with a time constant of 5 s1) followed
by a monoexponential increase with a rate of 0.21 s1, and
the steady-state phosphoenzyme level was 0.036 nmol
EP/mg total protein (0.048 nmol EP/nmol SERCA2a). The
presence of a lag phase in the EP formation time course is
consistent with the fact that a series of kinetic steps precedes
phosphoryl transfer from ATP to the enzyme (Frost and
Pearson, 1953). Pretreatment of the sample with anti-phos-
pholamban monoclonal antibody had no effect on the phos-
phoenzyme formation time course (Table 3). When coex-
pressed with wild-type phospholamban, the steady-state Ca-
ATPase phosphoenzyme level (0.007 nmol EP/mg
protein  0.026 nmol EP/nmol SERCA2a) was decreased
33% relative to samples pretreated with anti-phospholam-
ban monoclonal antibody (0.011 nmol EP/mg protein 
0.040 nmol EP/nmol SERCA2a), but neither the lag pre-
ceding EP formation (time constant of 1.8 s1) nor the
apparent rate of EP formation (0.18 s1) was changed
relative to the antibody-treated samples (0.18 s1). When
coexpressed with the more potent monomeric L37A-phos-
pholamban mutant, the steady-state Ca-ATPase phosphoen-
TABLE 2 Inhibitory effects of phospholamban (wild-type or L37A-PLB) on the [Ca2] dependence of steady-state SERCA2a
phosphoenzyme levels at 0°C using 1 M Mg[-32P]ATP
Maximum EP level KCa
Ab Ab Ab Ab
(nmol EP/nmol SERCA2a) (M)
SERCA2a alone 0.075  0.002 0.071  0.002 0.22  0.03 0.19  0.03
SERCA2a  WT-PLB 0.076  0.003 0.079  0.003 0.46  0.02 0.25  0.02
SERCA2a  L37A-PLB 0.077  0.003 0.075  0.003 0.80  0.03 0.40  0.03
Sf21 insect cell microsomes containing SERCA2a alone or SERCA2a  phospholamban (wild-type or L37A-PLB) were phosphorylated for 30 s at 0°C,
using 1 M Mg[-32P]ATP at various [Ca2]free, as depicted in Fig. 2. The sigmoidal curves were fit by the Hill equation, which provided the maximum
level of phosphoenzyme (EP) formation and the [Ca2] required for half-maximum phosphoenzyme formation (KCa). EP levels are expressed in terms of
nmol EP per nmol SERCA2a, according to the amount of SERCA2a per mg of Sf21 cell microsomes for each sample (Table 1). Samples were preincubated
in the absence (Ab) or presence (Ab) of anti-phospholamban monoclonal antibody, 2D12, for 20 min on ice before the start of the phosphorylation
experiments. Errors denote the spread of triplicate determinations for a single experiment using a single preparation of expressed protein. Experimental
repeats using different preparations gave very similar results.
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zyme level (0.006 nmol EP/mg protein  0.016 nmol EP/
nmol SERCA2a) was decreased by 45% relative to the
sample pretreated with anti-phospholamban antibody (0.011
nmol EP/mg protein  0.029 nmol EP/nmol SERCA2a),
but again neither the lag preceding EP formation (time
constant of 0.5 s1) nor the apparent rate of EP formation
(0.22 s1) was changed relative to samples pretreated with
anti-phospholamban monoclonal antibody (0.22 s1).
FIGURE 3 Time course of phosphoenzyme formation by SERCA2a in Sf21 microsomes by 1 M ATP at 0°C. SERCA2a phosphorylation time courses
were measured by adding 1 M [-32P]ATP and either 0.5 mM CaCl2 (268 nM ionized Ca
2, left panels) or 1.0 mM CaCl2 (15 M ionized Ca
2, right
panels) to Sf21 microsomes (0.1 mg/ml) preincubated in 1 mM EGTA (final conditions). The reaction was allow to proceed at 0°C for serial times as
indicated, followed by acid quenching and processing as described in Materials and Methods. (Top) SERCA2a expressed alone; (middle) SERCA2a 
wild-type phospholamban; (bottom) SERCA2a  L37A-phospholamban. Phosphorylation of SERCA2a in Sf21 microsomes pretreated with phospholam-
ban monoclonal antibody, 2D12, are denoted by filled circles (F), and the control, untreated microsomes are denoted by the empty circles (E). The solid
curves represent simulation of the EP formation time course, using the reactions of Scheme 3 and the rate constants in Table 6. The dotted curves represent
simulations where the values of k3 and k3 (Table 6) were each decreased by a factor of 10. Symbols represent the average of triplicate measurements for
a single preparation of each sample type. Error bars represent high and low values in each average. Additional experiments using different preparations
provided equivalent results.
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At 15 M [Ca2]free (Fig. 3, right), the apparent rate of
EP formation (0.38 s1) and the steady-state EP level (0.076
nmol EP/nmol SERCA2a) were similar for each of the
samples (Table 3). In addition, there was no discernible lag
phase preceding EP formation for any of the expressed
SERCA2a samples. Before the steady-state EP levels were
adjusted for the amount of SERCA2a in each sample type,
the steady-state EP levels were 0.055 nmol EP/mg protein
for SERCA2a expressed alone, 0.021 nmol EP/mg protein
for SERCA2a wild-type phospholamban, and 0.030 nmol
EP/mg for SERCA2a  L37A-phospholamban. Pretreat-
ment of the three samples with anti-phospholamban mono-
clonal antibody had no effect on the rate of EP formation or
the steady-state EP level (Table 3). Additional EP formation
experiments, carried out at 625 nM [Ca2]free (not shown),
produced results entirely similar to those obtained at 268
nM ionized [Ca2]. Phospholamban had no effect on the
apparent rate of EP formation (0.26 s1 for each sample, 
antibody treatment), but treatment of the phospholamban-
containing samples with anti-phospholamban antibody re-
sulted in a stimulation of the steady-state EP level of the
wild-type phospholamban sample by 30% and of the more
potent L37A-phospholamban sample by 70%. In summary,
the results of the phosphoenzyme formation studies show
that phospholamban does not affect the apparent rate of EP
formation. Because the apparent rate of SERCA2a phos-
phorylation is directly controlled by the rate of the Ca-
ATPase E1Ca-to-E1Ca transition under the conditions of
our experiments (Tada et al., 1980; Cantilina et al., 1993),
the results do not support the hypothesis that phospholam-
ban inhibits this transition in the SERCA2a cycle.
SERCA2a Pi liberation and
phosphoenzyme decomposition
The second goal of our kinetics studies was to test the
hypothesis that phospholamban inhibits Ca-ATPase cycling
by decreasing the rate of EP decomposition (step 5, Scheme
1). To test this hypothesis, we measured the effect of phos-
pholamban coexpression on the time course of Pi release
(Fig. 4 and Table 4), concomitant with our EP formation
experiments. This was accomplished by collecting an ali-
quot of the EP reaction mixture for each sample after the
quenched membranes were pelletted. The unreacted radio-
labeled ATP was removed from the sample by charcoal
extraction, and the 32Pi in the aliquot was separated by
complexation with ammonium molybdate and extraction
into organic solvent. The Pi liberation time courses for all
samples at both 268 nM and 15 M [Ca2]free exhibited a
brief lag (5–7 s), which coincided with the build-up of
SERCA2a EP, followed by a linear increase in Pi over time
during the steady-state phase of SERCA2a turnover. At 268
nM ionized [Ca2], the rate of Pi liberation for SERCA2a
TABLE 3 SERCA2a phosphoenzyme formation fit parameters
ionized [Ca2]
268 nM 15 M
k1 k2 EP level k1 EP level
(s1) (s1) (nmol/nmol SERCA2a) (s1) (nmol/nmol SERCA2a)
SERCA2a alone
Antibody 5.0  1.0 0.21  0.01 0.048  0.001 0.38  0.02 0.075  0.001
Antibody 5.0  1.0 0.21  0.01 0.048  0.001 0.38  0.02 0.075  0.001
Ratio (Ab/Ab) 1.0 1.0 1.0 1.0 1.0
SERCA2a  WT-PLB
Antibody 1.8  0.4 0.18  0.02 0.026  0.001 0.38  0.01 0.076  0.002
Antibody 1.8  0.4 0.18  0.02 0.040  0.001 0.38  0.01 0.076  0.002
Ratio (Ab/Ab) 1.0 1.0 1.5 1.0 1.0
SERCA2a  L37A-PLB
Antibody 0.5  0.1 0.22  0.01 0.016  0.001 0.38  0.01 0.077  0.001
Antibody 0.5  0.1 0.22  0.01 0.029  0.001 0.38  0.01 0.077  0.001
Ratio (Ab/Ab) 1.0 1.0 1.8 1.0 1.0
Phosphoenzyme (EP) formation time courses measured at 268 nM ionized [Ca2] (Fig. 3, left) were fit with a lag function (Frost and Pearson, 1953),
EP(t)  A0(1  A1e
k1t  A2e
k2t), where A0 is the amplitude (in nmol EP/nmol SERCA2a), k1 is the time constant for the lag phase (in s
1), k2 is the
rate of the monoexponential rise (in s1), A1  k2/(k1  k2), and A2  k1/(k1  k2). EP formation time courses measured at 15 M ionized Ca
2 (Fig.
3, right) were fit with a single-exponential function, EP(t)  A(1  ekt), where A is the amplitude (in nmol EP/nmol SERCA2a) and k is the rate (in s1).
Initial values of Ai and ki were obtained from semilog plots of the phosphoenzyme formation data but were allowed to vary freely during the fit. The only
constraint imposed was a minimum value of zero for each parameter. EP levels are expressed in terms of nmol EP per nmol SERCA2a, according to the
amount of SERCA2a per mg of Sf21 cell microsomes for each sample (Table 1). Errors denote the spread of triplicate determinations for a single experiment
using a single preparation of expressed protein. Experimental repeats using different preparations of the same sample types gave very similar
phosphoenzyme formation time courses.
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expressed alone was 3.6  103 nmol Pimg protein
1s1
(6.6  103 nmol Pinmol SERCA2a
1s1), and this rate
was not affected by pretreatment of the sample with anti-
phospholamban monoclonal antibody. When coexpressed
with wild-type phospholamban, the rate of Pi liberation by
SERCA2a (1.3  103 nmol Pimg protein
1s1 or 4.5 
103 nmol Pinmol SERCA2a
1s1) was decreased 33%
relative to the sample pretreated with anti-phospholamban
monoclonal antibody (2.0 103 nmol Pimg protein
1s1
or 7.0  103 nmol Pinmol SERCA2a
1s1). When co-
FIGURE 4 Time course of phosphate liberation by SERCA2a in Sf21 microsomes in the presence of 1 M ATP at 0°C. SERCA2a phosphorylation time
courses were measured as described in the legend of Fig. 3. Inorganic phosphate in each sample was isolated and processed as described in Materials and
Methods. (Top) SERCA2a expressed alone; (middle) SERCA2a  wild-type phospholamban; (bottom) SERCA2a  L37A-phospholamban. Phosphory-
lation of SERCA2a in Sf21 microsomes pretreated with phospholamban monoclonal antibody, 2D12, is denoted by filled circles (F), and the control,
untreated microsomes are denoted by the empty circles (E). The solid curves represent simulation of the Pi liberation time course, using the reactions of
Scheme 3 and the rate constants in Table 6. The dotted curves represent simulations where the values of k3 and k3 (Table 6) were each decreased by a
factor of 10. Symbols represent the average of triplicate measurements for a single preparation of each sample type (Table 4). Error bars represent high
and low values in each average. Additional experiments using different preparations provided equivalent results.
1316 Mahaney et al.
Biophysical Journal 78(3) 1306–1323
expressed with the more potent monomeric L37A-phospho-
lamban mutant, the rate of Pi liberation by SERCA2a (1.9
103 nmol Pimg protein
1s1 or 4.5 103 nmol Pinmol
SERCA2a1s1) was decreased by 45% relative to the
sample pretreated with anti-phospholamban antibody
(3.3  103 nmol Pimg protein
1s1 or 8.0  103 nmol
Pinmol SERCA2a
1s1). At 15 M [Ca2]free, the rate of
Pi liberation by SERCA2a in each of the expressed samples
was unaffected by pretreatment with anti-phospholamban
monoclonal antibody. When the raw Pi liberation rates
(4.4  103 (SERCA2a), 5.3  103 (SERCA2a  wild-
type phospholamban), and 5.9 103 (SERCA2a L37A-
phospholamban) nmol Pimg protein
1s1) were corrected
for differences in Ca-ATPase expression levels in the dif-
ferent samples (Table 1), the three samples showed essen-
tially the same rates: 0.010 (SERCA2a alone), 0.011
(SERCA2a  wild-type phospholamban) and 0.015
(SERCA2a  L37A-phospholamban) nmol Pinmol
SERCA2a1s1 (Table 4). Thus, even for the enzyme at
0°C with micromolar ATP concentration, inhibition of over-
all ATP hydrolysis by phospholamban occurs only at sub-
saturating ionized Ca2 concentrations, and there is no
apparent Vmax effect. Additional Pi liberation experiments,
carried out at 625 nM [Ca2]free (not shown), produced
results entirely similar to those obtained at 268 nM ionized
[Ca2]. Treatment of the phospholamban-containing sam-
ples with anti-phospholamban antibody 2D12 stimulated the
rate of Pi liberation by the wild-type phospholamban sample
by 30% and that of the more potent L37A-phospholamban
sample by 45%. Taken together, the results show that phos-
pholamban inhibits the apparent rate of product formation
by SERCA2a.
Correlation of the Pi liberation and EP formation data
showed that phospholamban (both wild-type and L37A-
phospholamban) inhibited the rate of Pi liberation to the
same extent as the inhibition of the steady-state EP level in
each sample. Because product formation (Pi) depends on the
rate of EP decomposition and the concentration of EP in the
steady state (d[Pi]/dt  k  [EP]), it appeared that the
phospholamban-mediated reduction in the rate of Pi produc-
tion was due to the decreased steady-state level of EP
induced by phospholamban. Alternatively, phospholamban
could have inhibited the rate of EP decomposition, resulting
in the reduced rate of Pi liberation. To distinguish further
between these two possibilities, we measured the effect of
phospholamban on the rate of SERCA2a phosphoenzyme
decomposition (Fig. 5). In this experiment, SERCA2a was
phosphorylated with 1 M ATP for 30 s at 0°C, which was
sufficient time for the system to attain steady-state EP levels
(Fig. 3). At 30 s, 5 mM EGTA (final concentration) was
added to the reaction mixture to remove all traces of ionized
Ca2 from the reaction mixture and thus to stop SERCA2a
phosphorylation by ATP. The phosphoenzyme present at
the time of the EGTA addition decayed with an exponential
time course, which was followed by quenching of the decay
reaction at serial times after EGTA addition.
Fig. 5 shows the effect of phospholamban on the time
course of EP decomposition by SERCA2a in Sf21 cell
microsomes at 0°C. The decomposition time course for all
samples was best fit by a monoexponential function. For
each sample at each [Ca2], the EP level at the zero time of
the EP decay time course corresponded to the steady-state
EP level measured in the EP formation experiments (Fig. 3
and Table 3). For phosphoenzyme formed at 268 nM
[Ca2]free, the apparent rate of EP decomposition in zero
ionized Ca2 was similar for all of the SERCA2a samples,
0.12 s1 for SERCA2a expressed alone, 0.15 s1 for
SERCA2a  wild-type phospholamban, and 0.14 s1 for
SERCA2a L37A-phospholamban (Table 5). Pretreatment
of the samples with anti-phospholamban monoclonal anti-
body had no effect on the rate of phosphoenzyme decay.
Additional experiments in which phosphoenzyme was
formed at 15 M [Ca2]free (Fig. 5 and Table 5) or 625 nM
[Ca2]free (not shown), but at which phosphoenzyme decay
proceeded at zero ionized Ca2, produced similar results.
The EP decomposition rate was nearly identical for all
samples (0.15 s1 at 625 nM [Ca2]free and 0.20 s
1 15 M
[Ca2]free), and the rate was not affected by pretreatment
with anti-phospholamban antibody. These results show that
phospholamban does not alter the rate of SERCA2a phos-
phoenzyme decomposition occurring in the absence of sig-
nificant ionized Ca2. Thus we conclude that phospholam-
TABLE 4 Steady-state Pi liberation fit parameters
[Ca2]free
268 nM rate 15 M rate
(nmol Pi  nmol
SERCA2a1  s1)
(nmol Pi  nmol
SERCA2a1  s1)
SERCA2a alone
Antibody 0.0066  0.0004 0.010  0.005
Antibody 0.0066  0.0004 0.010  0.005
Ratio (Ab/Ab) 1.0 1.1
SERCA2a  WT-PLB
Antibody 0.0045  0.001 0.011  0.001
Antibody 0.0070  0.001 0.011  0.001
Ratio (Ab/Ab) 1.5 1.0
SERCA2a  L37A-PLB
Antibody 0.0044  0.0008 0.015  0.001
Antibody 0.0080  0.0008 0.0015  0.001
Ratio (Ab/Ab) 1.8 1.0
Inorganic phosphate (Pi) liberation time courses (Fig. 4) were measured in
conjunction with phosphoenzyme formation experiments (Fig. 3). The
steady-state rate of Pi production was determined by fitting the linear phase
(from 15 to 60 s) of the Pi liberation time course. Pi liberation rates are
expressed in terms of nmol Pi  nmol SERCA2a
1  s1, according to the
amount of SERCA2a per mg of Sf21 cell microsomes for each sample
(Table 1). Errors denote the spread of triplicate determinations for a single
experiment using a single preparation of expressed protein. Experimental
repeats using different preparations of the same sample type gave very
similar Pi liberation curves.
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ban does not inhibit the rate of EP decay. Therefore,
phospholamban inhibits Pi liberation as a consequence of
the phospholamban-dependent reduction of steady-state
SERCA2a EP levels, rather than by directly inhibiting the
rate of EP decay.
Simulation of SERCA2a kinetics data
To determine the kinetic step(s) in the Ca-ATPase cycle
affected by phospholamban that would result in a decreased
steady-state EP level but no change in the rate of EP
FIGURE 5 Time course of phosphoenzyme decomposition by SERCA2a in Sf21 microsomes after a 5 mM EGTA chase at 0°C. SERCA2a in Sf21
microsomes (0.1 mg/ml) preincubated in 1 mM EGTA was phosphorylated by 1 M [-32P]ATP and either 0.5 mM CaCl2 (268 nM ionized Ca
2, left
panels) or 1.0 mM CaCl2 (15 M ionized Ca
2, right panels) at 0°C (final conditions). After 30 s of phosphorylation, 5 mM EGTA (final) was added to
the reaction to halt subsequent EP formation, and the decay of radiolabeled EP at 0°C was monitored by acid quenching the sample at serial times as
indicated. The samples were processed as described in Materials and Methods. (Top) SERCA2a expressed alone; (middle) SERCA2a  wild-type
phospholamban; (bottom) SERCA2a  L37A-phospholamban. Phosphoenzyme decomposition of SERCA2a in Sf21 microsomes pretreated with
phospholamban monoclonal antibody, 2D12, is denoted by filled circles (F), and the control, untreated microsomes are denoted by empty circles (E). The
solid curves represent simulation of the EP decay time course, using the reactions of Scheme 3 and the rate constants in Table 6. Symbols represent the
average of triplicate measurements for a single preparation of each sample type. Error bars represent high and low values in each average. Additional
experiments using different preparations provided equivalent results.
1318 Mahaney et al.
Biophysical Journal 78(3) 1306–1323
formation or decay, the [Ca2]-dependent steady-state EP
level and the time courses of EP formation, Pi liberation,
and EP decay for each sample were simulated using the
reactions of Scheme 3 and the rate constants presented in
Table 6. The details of the simulations are presented in
Materials and Methods. We first simulated the EP formation
and Pi liberation time courses measured for the SERCA2a
alone sample (Figs. 3 and 4, top, solid lines), to generate a
set of rate constants that described the SERCA2a reaction
cycle in the absence of phospholamban (Table 6). The best
simulation of the data was obtained using a catalytic site
density of 0.08 nmol/mg protein (0.11 nmol/nmol
SERCA2a), based on the maximum amount of EP formed at
saturating Ca2 by the subsaturating, 1 M ATP concen-
tration used in the experiments. In the simulations, the rate
of EP formation was dependent primarily on the forward
rate of the E1Ca-to-E1Ca transition (step 3), whereas the
steady-state EP level was dependent both on the forward
and reverse rates (i.e., the equilibrium constant) of the first
Ca2 ion binding to E1 (step 2) and the forward rate of the
E1Ca-to-E1Ca transition (step 3). The rate of the E2-to-E1
transition (step 1) had only minor effects on the EP forma-
tion time course, provided the rate of k1 remained greater
than 0.1 s1. At lower values of k1, the simulated EP
formation did not fit the experimental data. The rate of the
second Ca2 ion binding to E1Ca (step 4), the rate of ATP
binding to E1Ca2 (step 5), and the rate of phosphoryl
transfer from ATP to the enzyme (step 6) had little influence
on the simulations, because the rates of these steps were
much faster than the adjacent slow steps (steps 3 and 7). The
rates of EP decomposition and Pi release (steps 7 and 8)
were selected to allow the phosphoenzyme to rise to its
steady-state level without passing through an “overshoot,”
while simultaneously matching the lag and linear phases of
the Pi liberation time course. Some minor adjustments in
steps 7 and 8 were required to produce a more precise
simulation of the steady-state phase of EP formation and Pi
liberation at each ionized [Ca2] studied, but the selected
rates for steps 7 and 8 were verified by simulating the
SERCA2a alone EP decay data at each Ca2 level (Fig. 5,
top, solid lines). By carrying out the same simulation at a
series of ionized [Ca2] between 0 and 15 M, the [Ca2]
dependence of the steady-state EP levels were accurately
reproduced (Fig. 2, solid symbols). This result validated
Scheme 3 and the kinetic constants of Table 6 as an appro-
priate model for simulating SERCA2a kinetics under our
experimental conditions and for elucidating the effect of
phospholamban on the SERCA2a reaction cycle.
Simulation of the kinetics data from the SERCA2a 
wild-type phospholamban and SERCA2a  L37A-phos-
pholamban microsomes (Figs. 3–5, solid lines) was carried
out using a catalytic site density of 0.04 nmol/mg for the
SERCA2a  wild-type phospholamban microsomes and
0.07 nmol/mg for the SERCA2a  L37A-phospholamban
microsomes. The antibody-treated SERCA2a  wild-type
TABLE 5 Phosphoenzyme decomposition rate constants
[Ca2]free
268 nM rate 15 M rate
(s1) (s1)
SERCA2a alone
Antibody 0.12  0.02 0.19  0.04
Antibody 0.12  0.02 0.19  0.04
SERCA2a  WT-PLB
Antibody 0.15  0.02 0.20  0.03
Antibody 0.15  0.02 0.20  0.03
SERCA2a  L37A-PLB
Antibody 0.14  0.03 0.20  0.02
Antibody 0.14  0.03 0.20  0.02
Phosphoenzyme decomposition curves in Fig. 5 were fit with a single-
exponential function, EP(t)  Aekt, where A is the amplitude (in nmol
EP/nmol SERCA2a) and k is the rate (in s1). Initial values of A and k were
obtained from semilog plots of the phosphoenzyme decomposition data but
were allowed to vary freely during the fit. The only constraint imposed was
a minimum value of zero for each parameter. Errors denote the spread of
triplicate determinations for a single experiment using a single preparation
of expressed protein. Experimental repeats using different preparations
gave very similar phosphoenzyme formation time courses.
Scheme 3
TABLE 6 Kinetic constants for simulation of steady-state EP
levels and EP formation and Pi liberation time courses of
SERCA2a expressed alone in Sf21 insect cell microsomes
Reaction step
of Scheme 3 Rate constants
k1/k1 0.35 s
1/0.35 s1
k2/k2 2  10
8 M1 s1/120 s1
k3/k3 0.4 s
1/0.4 s1
k4/k4 8  10
7 M1 s1/3.2 s1
k5/k5 4  10
6 M1 s1/0
k6/k6 35 s
1/0
k7/k7 0.3 s
1/0.7 s1
k8/k8 0.5 s
1/0
Rate constants for the reaction mechanism shown in Scheme 3 were
evaluated by simulation of the [Ca2] dependence of steady-state phos-
phoenzyme (EP) levels (Fig. 2) and the EP formation (Fig. 3) and Pi
liberation (Fig. 4) time courses, using the program KINSIM (Barshop et al.,
1983). All rate constants were allowed to vary freely during the simulation,
with the exception that a minimum value of zero was imposed for each rate.
Additional details for the simulations are provided in the text.
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phospholamban and SERCA2a  L37A-phospholamban
kinetics data (Figs. 3 and 4, solid lines) was simulated using
the same kinetics constants used for the expressed
SERCA2a microsomes, except that for the SERCA2a 
L37A-phospholamban microsomes it was necessary to re-
duce by twofold the forward rate (k2) of step 2 (Ca
2
binding to E1) to 1  108 M1 s1, to properly reproduce
the rate and amplitude of the EP formation and Pi liberation
time courses. Similar to the SERCA2a alone sample, some
minor adjustments for steps 7 and 8 were required to pro-
duce a precise simulation of the EP formation and Pi liber-
ation time courses measured at the various ionized [Ca2]
studied, but the selected rates for steps 7 and 8 were verified
by simulating the EP decay data at each Ca2 level (Fig. 5,
solid lines). Finally, by carrying out the simulations at a
series of ionized [Ca2] levels between 0 and 15 M, the
[Ca2] dependence of the steady-state EP levels for both
antibody-treated samples were accurately reproduced (Fig.
2, solid symbols).
Two approaches were used to simulate the effect of
coexpressed phospholamban on SERCA2a kinetics data ob-
tained at 268 nM ionized [Ca2] (Figs. 3 and 4). First, we
tested the proposal by Cantilina et al. (1993) that phospho-
lamban decreases the forward and reverse rates of the
E1Ca-to-E1Ca transition (step 3, Scheme 3) by 10-fold.
Changing k3 and k3 from 0.4 s
1 to 0.04 s1 resulted in EP
formation (Fig. 3, left, dashed lines) and Pi liberation (Fig.
4, left, dashed lines) time courses that did not fit the data
obtained from the two phospholamban-containing samples.
Similar results were obtained when the untreated kinetics
data obtained at 625 nM (not shown) were simulated, and
even at saturating [Ca2] (also not shown), where there
should be no difference between untreated and antibody-
treated data (Figs. 3–5). Therefore, the results of this ap-
proach suggest that phospholamban does not inhibit
SERCA2a EP formation by inhibiting the E1Ca-to-E1Ca
transition.
We next focused on Ca2 binding to E1 (step 2, Scheme
3) as a target for phospholamban inhibition, because our
simulations showed that the kinetic constants for this step
had substantial effects on the steady-state EP level but only
minor effects on the rate of EP formation in the simulations
(see above). For both the SERCA2a  wild-type phospho-
lamban and the SERCA2a  L37A-phospholamban kinet-
ics data, a twofold decrease in the equilibrium constant
(Keq) for step 2 was sufficient, by itself, to simulate the
untreated EP formation and Pi liberation time courses at
both 268 nM (Figs. 3 and 4, left, solid lines) and 625 nM
(not shown) ionized [Ca2]. For the SERCA2a  wild-type
phospholamban microsomes, k2 was reduced to 1  10
8
M1 s1, whereas for the SERCA2a  L37A-phospholam-
ban microsomes, k2 was reduced to 5  10
7 M1 s1. (The
same result was achieved by holding k2 constant and in-
creasing k2 by a factor of 2 to 240 s
1 for both samples.)
At 15 M ionized Ca2, the twofold decrease in k2 had no
effect on the simulated kinetics; the EP formation, Pi liber-
ation, and EP decay time courses generated were identical to
the simulations of the antibody-treated data. This result was
validated by conducting the simulation at a series of ionized
[Ca2], which accurately reproduced the [Ca2] depen-
dence of the steady-state EP levels measured for both un-
treated samples (Fig. 2, solid symbols). Thus the results of
the simulations show that wild-type phospholamban inhibits
SERCA2a by decreasing by twofold the equilibrium bind-
ing of the first Ca2 to E1 relative to the SERCA2a alone
sample. L37A-phospholamban is more potent than wild-
type phospholamban, because it decreases equilibrium Ca2
binding to E1 by fourfold relative to the SERCA2a alone
sample. Nevertheless, high ionized [Ca2] is capable of
reversing the inhibitory effect of phospholamban on
SERCA2a completely, even the inhibition by the more
potent L37A-phospholamban mutant.
DISCUSSION
In the present study, we have measured the effects of
phospholamban on the time course of Ca-ATPase phosphor-
ylation by ATP, to test the hypothesis (Cantilina et al.,
1993) that phospholamban inhibits Ca-ATPase cycling by
decreasing by 10-fold the rate of the E1Ca-to-E1Ca tran-
sition (Scheme 2). Likewise, we have measured the effects
of phospholamban on the time courses of inorganic phos-
phate (Pi) liberation and phosphoenzyme (EP) decomposi-
tion, to test the hypothesis that phospholamban inhibits
steady-state ATPase activity by decreasing the rate of
SERCA2a EP decay. To assist in this work, we have made
use of the baculovirus-Sf21 insect cell expression system
(Autry and Jones, 1997) to produce microsomes containing
1) Ca-ATPase alone, 2) Ca-ATPase coexpressed with wild-
type phospholamban, and 3) Ca-ATPase coexpressed with
the monomeric L37A-phospholamban mutant (L37A-phos-
pholamban). To further define the specific effects of phos-
pholamban on SERCA2a kinetics, we used a monoclonal
antibody against phospholamban to reverse phospholamban
inhibitory effects. The expressed SERCA2a samples had the
same specific ATPase activity as SERCA2a in dog cardiac
SR, and the SERCA2a in the expressed samples was phos-
phorylated to the same extent as SERCA2a in dog cardiac
SR. The inhibitory effects of wild-type phospholamban on
SERCA2a in the expressed sample were nearly identical to
those measured for cardiac SR, and pretreatment with anti-
phospholamban antibody relieved the inhibition to the same
extent in the two samples. Because of the relatively high
levels of SERCA2a and phospholamban expression pro-
vided by the baculovirus-Sf21 insect cell expression system,
we were able to measure the effects of phospholamban on
the phosphorylation and dephosphorylation kinetics of the
expressed SERCA2a for the first time. Furthermore, the
yield of SERCA2a from a single preparation provided suf-
ficient material to carry out all of the experiments shown
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here for each sample type. This is advantageous, because
the results from several different types of kinetics experi-
ments can be compared directly without having to correct
for individual preparation differences. Our kinetics studies
corroborate previous reports (Autry and Jones, 1997;
Kimura et al., 1997) that L37A-phospholamban is a more
potent inhibitor of the Ca-ATPase than wild-type phospho-
lamban. At low ionized [Ca2] (268 nM and 625 nM), we
found that L37A-phospholamban decreased the steady-state
EP level and the apparent rate of Pi liberation to a greater
extent (45%) than did wild-type phospholamban (33%).
Despite being the more potent regulator, L37A-phospho-
lamban, like wild-type phospholamban, did not affect the
rates of SERCA2a EP formation or decomposition relative
to SERCA2a in the absence of phospholamban. The results
of our steady-state EP level studies also confirm the find-
ings of other reports (Kranias, 1985; Cantilina et al., 1993;
Autry and Jones, 1997; Chu et al., 1998) that phospholam-
ban, even the more potent L37A-phospholamban mutant,
does not affect SERCA2a Vmax or the maximum steady-
state EP levels at saturating [Ca2].
A number of investigators (Tada et al., 1979; Antipenko
et al., 1997a, 1999) have reported that phospholamban in-
hibits SERCA2a by decreasing the rate of phosphoenzyme
hydrolysis (step 5, Scheme 1). Most of these studies, how-
ever, were done with dog cardiac SR, in which phospho-
lamban was always present and in which phospholamban
inhibitory effects had to be reversed by phospholamban
phosphorylation. Our EP decomposition results, obtained
with a more controllable system, disagree with these re-
ports, showing that phospholamban, even the more potent
L37A-phospholamban mutant, does not affect the rate of EP
decomposition. This may be due, in part, to the significant
differences in reaction conditions (temperature, [ATP],
[Ca2], etc.) between our kinetics studies and previous
reports. Of these differences, the [ATP] may be the most
important, because high ATP concentrations have been sug-
gested to increase the rate of EP decomposition and turn-
over (Inesi, 1985), and McKenna and co-workers (McK-
enna et al., 1996; Coll et al., 1999) have demonstrated a
relationship between nucleotide activation of SERCA2a and
phospholamban regulation of SERCA2a activity. However,
it is unlikely that our reaction conditions prevented us from
observing an effect of phospholamban on the rate of
SERCA2a EP decomposition. Phosphoenzyme decomposi-
tion reduces steady-state EP levels by reducing the number
of phosphorylated enzymes. If phospholamban inhibits the
rate of EP decomposition, we would expect to observe a
greater fraction of phosphorylated enzymes during steady-
state enzyme cycling—hence increased steady-state phos-
phoenzyme levels, when phospholamban is regulatory rel-
ative to samples pretreated with anti-phospholamban
antibody to remove phospholamban inhibition. This clearly
was not the case. Rather, we found that phospholamban
decreased the SERCA2a steady-state EP level and, as a
result, reduced the rate of Pi production to the same extent.
Therefore, we conclude that phospholamban shifts the
[Ca2] dependence of Pi production (i.e., ATPase activity)
by a similar shift in the [Ca2] dependence of steady-state
EP levels (as described below), and not by affecting the rate
of EP decay. This conclusion is best supported by our
finding of nearly identical effects of phospholamban on the
[Ca2] dependence of steady-state EP levels and ATPase
activity.
A number of other investigators (Cantilina et al., 1993;
Negash et al., 1996; Antipenko et al., 1997a) have proposed
that phospholamban inhibits Ca-ATPase cycling by increas-
ing the activation energy of the E1Ca-to-E1Ca conforma-
tional change (Scheme 2). Our EP formation studies were
designed to quantitatively test this proposal as follows. The
Ca-ATPase was preincubated in 1 mM EGTA to remove all
traces of Ca2 from the medium and thereby stabilize the
enzyme in a Ca2-free state. At time 0, ATP and CaCl2
were simultaneously added to the enzyme, and the apparent
rate of ATP-dependent phosphorylation was measured. Un-
der these conditions, Ca2 must first bind to the Ca-ATPase
E1 intermediate and stimulate the formation of the E1Ca2
intermediate before ATP-dependent phosphorylation can
occur (Scheme 2). According to Cantilina et al. (1993), the
E1Ca-to-E1Ca transition (step 2, Scheme 2) is the rate-
determining step preceding phosphoryl transfer from ATP
to the enzyme (see figure 10 of Cantilina et al., 1993), such
that the apparent rate of SERCA2a phosphorylation should
be determined largely by the rate of this transition. There-
fore, if phospholamban decreases the rate of the E1Ca-to-
E1Ca transition by 10-fold, we would expect to observe a
clear difference in the apparent rate of phosphoenzyme
formation between the control samples and samples pre-
treated with a monoclonal antibody against phospholamban,
2D12, which uncouples phospholamban from the Ca-
ATPase. However, our results did not support this. Our EP
formation data at 268 nM ionized Ca2 (Fig. 3 and Table 3)
and 625 nM ionized Ca2 (not shown) indicated no differ-
ence in the apparent rate of EP formation before or after
antibody treatment. Thus we conclude that phospholamban
does not inhibit Ca-ATPase cycling by decreasing the rate
of the E1Ca-to-E1Ca transition.
Additional evidence to rule out a phospholamban effect
on the SERCA2a E1Ca-to-E1Ca transition was provided
by our simulations. Similar to the results of Cantilina et al.
(1993), the rate of the E1Ca-to-E1Ca transition in our
model (Scheme 3 and Table 6) limits the rate of EP forma-
tion and the steady-state EP level. Because the rates of EP
breakdown and the E2-to-E1 transition are similar to that of
the E1Ca-to-E1Ca transition, phosphoenzyme is formed
at about the same rate that it decays, giving rise to the
observed steady-state EP level. However, decreasing k3 and
k3 by 10-fold makes the rate of EP formation much slower
than the rate of EP decay, resulting in very low steady-state
EP levels, with concomitantly low rates of Pi liberation (Fig.
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3 and 4, dashed lines). Even at saturating (15 M) ionized
[Ca2], a 10-fold decrease in the bidirectional rate of step 3
dramatically slows the rate of EP formation and decreases
the steady-state EP level (not shown). These changes clearly
do not match the observed effects of phospholamban on
SERCA2a kinetics. Therefore, our simulations corroborate
the conclusion that phospholamban does not inhibit Ca-
ATPase cycling by decreasing the rate of the E1Ca-to-
E1Ca transition.
In contrast, our simulations indicated that phospholam-
ban inhibits SERCA2a activity by decreasing the equilib-
rium binding of the first Ca2 to E1 (step 2, Scheme 3).
Proper simulation of our kinetics data was obtained using
k2  2  10
8 M1 s1 and k2  120 s
1, resulting in an
equilibrium constant for the first Ca2 binding (Keq, 2; step
2) of 1.66  106 M1, and k4  8  10
7 M1 s1 and k4
 3.2 s1, resulting in an equilibrium constant for the
second Ca2 binding (Keq, 4; step 4) of 2.5  10
7 M1.
Therefore, the equilibrium constant for the second Ca2
binding was larger than that for the first Ca2 binding,
which satisfied the condition for positive cooperativity of
Ca2 binding. At all ionized [Ca2] levels studied, Ca2
was in great excess over the concentration of enzyme,
allowing us to consider the forward reactions of steps 2 and
4 in pseudo-first-order terms. For example, at 268 nM
ionized [Ca2], k2 was 54 s
1, resulting in an effective
Keq, 2 of 0.45, and k4 was 21 s
1, resulting in an effective
Keq, 4 of 6.6. As such, the amount of E1Ca2 available for
phosphorylation by ATP (i.e., the steady-state EP level) was
controlled largely by the equilibrium of step 2, which fa-
vored Ca2 dissociation from the enzyme. Thus, by impos-
ing a twofold decrease in the affinity of SERCA2a for the
first Ca2, phospholamban effectively reduced the amount
of enzyme that was catalytically activated (E1Ca2) to split
ATP and transport Ca2. This accounts for the greater
potency of L37A-phospholamban as a SERCA2a inhibitor
than wild-type phospholamban, because L37A-phospho-
lamban reduces the Ca2 binding equilibrium to a greater
extent (fourfold) than does wild-type phospholamban (two-
fold). In contrast, at 15 M ionized [Ca2], k2 was 3000
s1, resulting in an effective Keq, 2 of 25, and k4 was 1200
s1, resulting in an effective Keq, 4 of 375. Under these
conditions, a two- or fourfold decrease in SERCA2a affinity
for the first Ca2 imposed by phospholamban or L37A-
phospholamban, respectively, would have no effect on
SERCA2a kinetics, because the equilibrium would still
strongly favor the formation of E1Ca. Thus at high ionized
[Ca2], phospholamban would not have any influence over
SERCA2a kinetics. These effects are entirely consistent
with the well-documented inhibition of SERCA2a by phos-
pholamban; phospholamban decreases the apparent Ca2
affinity of SERCA2a and inhibits the enzyme at low ionized
[Ca2] levels, but not at saturating [Ca2]. Therefore, we
conclude that phospholamban inhibits SERCA2a by de-
creasing SERCA2a affinity for Ca2.
Our studies show that the quintessence of the phospho-
lamban effect on the Ca-ATPase is to lower the apparent
affinity of the enzyme for Ca2. Paradoxically, however,
when enzyme affinity for Ca2 was measured directly under
steady-state conditions in the previous study by Cantilina et
al. (1993), no effect of phospholamban on Ca2 affinity was
detected. However, Cantilina et al. measured Ca2 binding
to the Ca-ATPase under passive conditions (i.e., in the
absence of ATP and Mg), in which the enzyme was not
hydrolyzing ATP and not actively transporting Ca2. Our
results presented here make the novel prediction that equi-
librium Ca2 binding to the enzyme would be decreased by
phospholamban interaction with the Ca-ATPase, if the mea-
surement were to be made under conditions in which the
enzyme was actively transporting Ca2. Experiments are
currently in progress to test the hypothesis that phospho-
lamban lowers equilibrium Ca2 binding to the Ca-ATPase,
but only under the condition in which the enzyme is hydro-
lyzing ATP and actively transporting Ca2.
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